What is Roivant?
Founded in 2014 and headquartered in London, Roivant Sciences operates as a tech-enabled healthcare company. Its core mission is to accelerate the development of promising late-stage drug candidates and to deliver innovative healthcare technologies directly to patients. Roivant's unique model focuses on identifying and advancing assets that have the potential for significant patient impact, leveraging its technological capabilities to streamline the drug development process and bring novel treatments to market more efficiently.
How much funding has Roivant raised?
Roivant has raised a total of $1.4B across 3 funding rounds:
Private Equity
$100M
Private Equity
$1.1B
Private Equity
$200M
Private Equity (2014): $100M with participation from Dexcel Pharma and QVT Financial
Private Equity (2017): $1.1B led by Dexcel Pharma and Softbank
Private Equity (2018): $200M supported by RTW Investments and NovaQuest Capital Management
Key Investors in Roivant
Dexcel Pharma
Dexcel Pharma, Israel's largest privately owned pharmaceutical company, focuses on developing and commercializing branded prescription drugs, generics, and OTC products. They supply over 85 products across more than 175 dosage forms to international markets.
Softbank
SoftBank Group is a global technology holding company investing in telecommunications, internet services, AI, and clean energy. They support transformative technologies worldwide through platforms like the SoftBank Vision Fund.
RTW Investments
RTW is a life sciences investment firm specializing in biotech and medtech innovation across the entire company lifecycle. They partner with companies to provide capital and expertise, aiming to improve patient lives.
What's next for Roivant?
With substantial enterprise-level backing and a recent strategic investment, Roivant Sciences is poised for significant advancements. The company's focus on late-stage drug development and innovative healthcare technologies suggests a strategic direction aimed at commercialization and patient delivery. Future growth will likely involve expanding its pipeline, forging new partnerships, and potentially scaling its operations to meet the demands of a global healthcare market. The consistent inflow of capital indicates strong investor confidence in Roivant's business model and its potential to disrupt traditional pharmaceutical development.
See full Roivant company page
